Hy2Care, a spin-off from the MIRA Institute at the University of Twente, secured â¬4.5M funding to support its upcoming clinical trial in the U.S. Half of this funding comes from the European Innovation Council Fund, reinforcing their strategy for commercialization in Europe and globally. The approval of an FDA Investigational Device Exemption for their CartRevive hydrogel implant for cartilage repair marks a significant milestone for the company, which aims to complete patient enrollment for its EU trial in 2024 and seeks CE marking by early 2026.
This funding round gives us the momentum needed to take the next big step in our journey, launching U.S. clinical trials and supporting our European commercialization strategy.
Hy2Care has developed a patented hydrogel technology that aims to revolutionize knee cartilage repair with its flagship product, the CartRevive implant.
Collection
[
|
...
]